Real-world early outcomes of axicabtagene ciloleucel for relapsed or refractory (R/R) follicular lymphoma (FL).

被引：0
|
作者：
Jacobson, Caron Alyce
Hemmer, Michael T.
Hu, Zhen-Huan
Frank, Matthew Joshua
Popplewell, Leslie
Ahmed, Nausheen
Lin, Yi
Best, Timothy
Beygi, Sara
Miao, Harry H.
Fu, Christine
Sun, Fang
Xu, Hairong
Pasquini, Marcelo C.
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Kite, Santa Monica, CA USA
[3] Stanford Univ, Stanford, CA USA
[4] City Hope Natl Med Ctr, Duarte, CA USA
[5] Univ Kansas, Med Ctr, Westwood, KS USA
[6] Mayo Clin, Rochester, MN USA
[7] Med Coll Wisconsin, CIBMTR, Dept Med, Milwaukee, WI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7509
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Real-World Experience of Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed or Refractory Aggressive B-cell Lymphomas: A Single-Institution Experience
    Ghafouri, Sanaz
    Fenerty, Kathleen
    Schiller, Gary
    de Vos, Sven
    Eradat, Herbert
    Timmerman, John
    Larson, Sarah
    Mead, Monica
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (12): : 861 - 872
  • [42] Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma
    Nath, Karthik
    Wudhikarn, Kitsada
    Alarcon Tomas, Ana
    Perales, Miguel-Angel
    EXPERT OPINION ON DRUG SAFETY, 2023, 22 (01) : 5 - 15
  • [43] ELARA Trial Update: Long-Term Clinical Outcomes and Correlative Efficacy Analyses of Tisagenlecleucel in Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL)
    Fowler, Nathan
    Dreyling, Martin
    Dickinson, Michael
    Martinez-Lopez, Joaquin
    Kolstad, Arne
    Butler, Jason
    Ghosh, Monalisa
    Popplewell, Leslie
    Chavez, Julio
    Bachy, Emmanuel
    Kato, Koji
    Harigae, Hideo
    Kersten, Marie Jose
    Andreadis, Charalambos
    Riedell, Peter
    Ho, P. Joy
    Antonio Perez-Simon, Jose
    Chen, Andy
    Nastoupil, Loretta
    von Tresckow, Bastian
    Ferreri, Andres Jose Maria
    Teshima, Takanori
    Patten, Piers
    McGuirk, Joseph
    Petzer, Andreas
    Offner, Fritz
    Viardot, Andreas
    Zinzani, Pier
    Malladi, Ram
    Paule, Ines
    Zia, Aiesha
    Awasthi, Rakesh
    Han, Xia
    Germano, Davide
    O'Donovan, Darragh
    Ramos, Roberto
    Masood, Aisha
    Thieblemont, Catherine
    Schuster, Stephen
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S534 - S535
  • [44] Updated outcomes with axicabtagene ciloleucel (axi-cel) retreatment (reTx) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) in ZUMA-5.
    Chavez, Julio C.
    Jacobson, Caron A.
    Sehgal, Alison
    Neelapu, Sattva Swarup
    Maloney, David G.
    Salles, Gilles A.
    William, Basem M.
    Yang, Yin
    Goyal, Lovely
    Chou, Justin
    Plaks, Vicki
    Avanzi, Mauro P.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [45] Trial in Progress: Follicular Lymphoma Outcomes in Relapsed/Refractory Patients Treated with Systemic Therapy in a Real-World Assessment (FLORA)
    Bachy, Emmanuel
    Damaj, Gandhi Laurent
    Ma, Qiufei
    Hampp, Christian
    Harnett, James
    Sobel, Rachel E.
    Jalbert, Jessica J.
    Quek, Ruben G. W.
    Wei, Wenhui
    Wu, Ning
    Mastey, Vera
    Wang, Joy
    Bajwa, Anit
    Maissenhaelter, Benedikt
    van Gils, Chantal
    Aggarwal, Shivani
    Chaudhry, Aafia
    Mohamed, Hesham
    Ambati, Srikanth R.
    Thieblemont, Catherine
    BLOOD, 2022, 140 : 5198 - 5200
  • [46] Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States
    Jacobson, Caron A.
    Locke, Frederick L.
    Ma, Long
    Asubonteng, Julius
    Hu, Zhen-Huan
    Siddiqi, Tanya
    Ahmed, Sairah
    Ghobadi, Armin
    Miklos, David Bernard
    Lin, Yi
    Perales, Miguel-Angel
    Lunning, Matthew Alexander
    Herr, Megan M.
    Hill, Brian T.
    Ganguly, Siddhartha
    Dong, Hua
    Nikiforow, Sarah
    Hooper, Michele
    Kawashima, Jun
    Xu, Hairong
    Pasquini, Marcelo C.
    TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (09): : 581.e1 - 581.e8
  • [47] Safety of Axicabtagene Ciloleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma
    Grana, Allison
    Gut, Natalia
    Williams, Kiersten
    Maakaron, Joseph
    Porter, Kyle
    William, Basem M.
    Vasu, Sumithira
    Penza, Sam
    Brammer, Jonathan E.
    Saad, Ayman
    Puto, Marcin
    Jaglowski, Samantha M.
    Roddy, Julianna
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (04): : 238 - 245
  • [48] Preliminary results of earlier steroid use with axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).
    Topp, Max S.
    van Meerten, Tom
    Wermke, Martin
    Lugtenburg, Elly J.
    Minnema, Monique C.
    Song, Kevin W.
    Thieblemont, Catherine
    Jiang, Yizhou
    Plaks, Vicki
    Kerber, Anne
    Kersten, Marie Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [49] Tafasitamab for the Treatment of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in the US Real-World Setting
    Saverno, Kimberly
    Savill, Kristin M. Zimmerman
    Feinberg, Bruce
    Galvin, John
    Pathak, Prathamesh
    Gordon, Sarah
    Amoloja, Theresa
    Llorente, Mae
    Epperla, Narendranath
    Nastoupil, Loretta J.
    BLOOD, 2023, 142
  • [50] TRANSCEND FL: phase 2 study results of lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL)
    Borchmann, Peter
    Morschhauser, Franck
    Dahiya, Saurabh
    Palomba, M. Lia
    Garcia-Sancho, Alejandro Martin
    Reguera Ortega, Juan Luis
    Kuruvilla, John
    Jaeger, Ulrich
    Cartron, Guillaume
    Izutsu, Koji
    Dreyling, Martin
    Kahl, Brad
    Ghesquieres, Herve
    Ardeshna, Kirit
    Goto, Hideki
    Barbui, Anna Maria
    Abramson, Jeremy S.
    Fleury, Isabelle
    Mielke, Stephan
    Farazi, Thalia
    Fasan, Omotayo
    Lymp, James
    Vedal, Min
    Nishii, Rina
    Avilion, Ariel
    Papuga, Jessica
    Nastoupil, Loretta J.
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 142 - 143
12345